Two weeks of daily tesamorelin (a GHRH peptide analog) significantly increased pulsatile growth hormone secretion and IGF-1 in healthy men without impairing insulin sensitivity.
IGF-1 increased by 181 μg/L (p<0.0001)Tesamorelin dramatically boosted IGF-1 while preserving insulin-stimulated glucose uptake, demonstrating that GHRH-based GH augmentation avoids the insulin resistance seen with direct GH replacement.
What the researchers found
Tesamorelin 2 mg daily for 2 weeks significantly increased:
- Mean overnight GH (+0.5 μg/liter, p = 0.004)
- Average GH peak area (p = 0.001)
- Basal GH secretion (+0.008 μg/liter·min, p = 0.008)
- IGF-1 (+181 μg/liter, p < 0.0001)
Critically, insulin-stimulated glucose uptake (measured by gold-standard euglycemic clamp) was not significantly affected (p = 0.61), and fasting glucose remained stable (p = 0.93). This demonstrates that GHRH-mediated GH augmentation preserves insulin sensitivity, unlike exogenous GH administration which can worsen insulin resistance.
Why it matters
People with excess belly fat have reduced growth hormone secretion, which may contribute to metabolic problems. Direct GH replacement can worsen insulin resistance, creating a therapeutic dilemma. Tesamorelin — by stimulating the body's own GH production through its natural pulsatile pattern — offers a potentially safer alternative. This study's demonstration of preserved insulin sensitivity is crucial for the drug's clinical application, particularly in metabolically vulnerable populations.
How the study worked
Open-label clinical study in 13 healthy males (mean age 45, mean BMI 27.3). Participants received tesamorelin 2 mg subcutaneously daily for 2 weeks, with assessments at baseline, end of treatment, and after 2 weeks of washout. GH pulsatility was measured via overnight frequent blood sampling. Insulin sensitivity was assessed using the gold-standard euglycemic hyperinsulinemic clamp technique.
What this study cannot tell us
Very small sample size (n=13) of healthy men only, limiting generalizability. The 2-week treatment period is short and does not capture long-term effects. The study lacked a placebo control group. Only healthy men were studied; effects in populations with GH deficiency, obesity, or HIV lipodystrophy (the approved indication) may differ. Pulse frequency was not significantly affected, only pulse amplitude and basal secretion.
How to read the evidence
This is a small, open-label clinical study without a placebo control. While it uses gold-standard endocrine measurements (overnight GH sampling and euglycemic clamp), the lack of blinding and small sample limit the strength of conclusions.
When this study was published
Published in 2011, this study predates tesamorelin's widespread clinical use. Subsequent larger trials and real-world data have further characterized the drug's effects, but this study provides important mechanistic insights into how tesamorelin augments natural GH physiology.
The bigger picture
Tesamorelin was subsequently approved by the FDA for reducing excess abdominal fat in HIV-associated lipodystrophy. This study provides foundational evidence for understanding its mechanism — augmenting natural GH pulsatility rather than simply flooding the system with GH. The preservation of insulin sensitivity distinguishes GHRH-based approaches from direct GH therapy and has important implications for the growing peptide community interested in growth hormone optimization.
Questions still open
- Does insulin sensitivity remain preserved with longer-term tesamorelin use (months to years)?
- Would tesamorelin produce similar GH augmentation in GH-deficient or obese individuals?
- How do the metabolic effects of tesamorelin-induced pulsatile GH compare to those of direct GH administration?
Common questions
How is tesamorelin different from taking growth hormone directly?
What is tesamorelin approved for?
Read the original research
Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.
The Journal of clinical endocrinology and metabolism, 96(1), 150-8
Citation
Stanley, Takara L; Chen, Cindy Y; Branch, Karen L; Makimura, Hideo; Grinspoon, Steven K. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.. The Journal of clinical endocrinology and metabolism, 96(1), 150-8. https://doi.org/10.1210/jc.2010-1587